NO975688L - Differensialanalyse for ulcerös kolitt, primær skleroserende cholangitt og type 1 autoimmunhepatitt - Google Patents

Differensialanalyse for ulcerös kolitt, primær skleroserende cholangitt og type 1 autoimmunhepatitt

Info

Publication number
NO975688L
NO975688L NO975688A NO975688A NO975688L NO 975688 L NO975688 L NO 975688L NO 975688 A NO975688 A NO 975688A NO 975688 A NO975688 A NO 975688A NO 975688 L NO975688 L NO 975688L
Authority
NO
Norway
Prior art keywords
ulcerative colitis
sclerosing cholangitis
primary sclerosing
type
autoimmune hepatitis
Prior art date
Application number
NO975688A
Other languages
English (en)
Other versions
NO975688D0 (no
NO321090B1 (no
Inventor
Stephan Targan
Alda Vidrich
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of NO975688D0 publication Critical patent/NO975688D0/no
Publication of NO975688L publication Critical patent/NO975688L/no
Publication of NO321090B1 publication Critical patent/NO321090B1/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Rehabilitation Therapy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO19975688A 1995-06-07 1997-12-05 Fremgangsmate for pavisning av naervaer av perinukleaert, antinoytrofilt, cytoplasmatisk antistoff (p-ANC) forbundet med type 1 autoimmunhepatitt og primaer, skleroserende cholangitt i en prove og fremgangsmate for a skille primaer, skleroserende cholangitt fra type 1 autoimmunhepatitt. NO321090B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/480,753 US5830675A (en) 1993-03-10 1995-06-07 Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis, primary sclerosing cholangitis, or type 1 autoimmune hepatitis
PCT/US1996/008758 WO1996041183A1 (en) 1995-06-07 1996-06-05 Differential assay for ulcerative colitis, primary sclerosing cholangitis and type 1 autoimmune hepatitis

Publications (3)

Publication Number Publication Date
NO975688D0 NO975688D0 (no) 1997-12-05
NO975688L true NO975688L (no) 1998-02-05
NO321090B1 NO321090B1 (no) 2006-03-13

Family

ID=23909233

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19975688A NO321090B1 (no) 1995-06-07 1997-12-05 Fremgangsmate for pavisning av naervaer av perinukleaert, antinoytrofilt, cytoplasmatisk antistoff (p-ANC) forbundet med type 1 autoimmunhepatitt og primaer, skleroserende cholangitt i en prove og fremgangsmate for a skille primaer, skleroserende cholangitt fra type 1 autoimmunhepatitt.

Country Status (12)

Country Link
US (1) US5830675A (no)
EP (1) EP0846266B1 (no)
JP (1) JP3386815B2 (no)
AT (1) ATE231972T1 (no)
AU (1) AU705480B2 (no)
CA (1) CA2223642C (no)
DE (1) DE69626026T2 (no)
IL (1) IL122480A0 (no)
MX (1) MX9709440A (no)
NO (1) NO321090B1 (no)
NZ (1) NZ310079A (no)
WO (1) WO1996041183A1 (no)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874233A (en) * 1996-04-12 1999-02-23 Cedars-Sinai Medical Center Methods of diagnosing a clinical subtype of Crohn's disease with features of ulcerative colitis
US6033864A (en) * 1996-04-12 2000-03-07 The Regents Of The University Of California Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens
IL126535A (en) * 1996-04-12 2002-11-10 Cedars Sinai Medical Center Diagnosis of ulcerative colitis and subtypes of the above using histone H1
US5968741A (en) * 1997-04-11 1999-10-19 Cedars-Sinai Medical Center Methods of diagnosing a medically resistant clinical subtype of ulcerative colitis
US6183951B1 (en) * 1997-04-11 2001-02-06 Prometheus Laboratories, Inc. Methods of diagnosing clinical subtypes of crohn's disease with characteristic responsiveness to anti-Th1 cytokine therapy
JP3267893B2 (ja) 1997-05-15 2002-03-25 鐘淵化学工業株式会社 自己免疫疾患の診断薬
US6599509B2 (en) * 1997-09-02 2003-07-29 Massachusetts Institute Of Technology Compositions and methods comprising helicobacter antigens for treatment and prevention of inflammatory bowel disease
DE19805815C1 (de) 1998-02-13 1999-11-11 Ansgar W Lohse Diagnostikum zum Erkennen der autoimmunen Hepatitis
US20080193945A1 (en) * 2002-06-25 2008-08-14 Index Diagnostics Ab Method and Kit for the Diagnosis of Ulcerative Colitis
US20040053263A1 (en) * 2002-08-30 2004-03-18 Abreu Maria T. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease
US20040076960A1 (en) * 2002-10-18 2004-04-22 Taylor Kent D. Methods of using a NOD2/CARD15 haplotype to diagnose Crohn's disease
US7662569B2 (en) * 2003-04-11 2010-02-16 Cedars-Sinai Medical Center Methods of assessing Crohn's disease patient phenotype by I2 serologic response
US7759079B2 (en) * 2004-05-13 2010-07-20 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
US20060154276A1 (en) 2004-05-13 2006-07-13 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
CN1316250C (zh) * 2005-05-01 2007-05-16 李小峰 中性粒细胞抗原底片的制备方法
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20100094560A1 (en) * 2006-08-15 2010-04-15 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
GB0621454D0 (en) * 2006-10-27 2006-12-06 Ucl Business Plc Goal directed therapy for liver failure
WO2008116150A2 (en) 2007-03-21 2008-09-25 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (ipaa) factors in the treatment of inflammatory bowel disease
DK2223121T3 (da) 2007-12-20 2012-10-22 Index Diagnostics Ab Publ Fremgangsmåde og kit til anvendelse ved differentiering mellem ibd og ibs og yderligere skelnen mellem ibd-sygdomstyper
WO2010056682A2 (en) 2008-11-11 2010-05-20 Prometheus Laboratories Inc. Methods for prediction of inflammatory bowel disease (ibd) using serologic markers
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
US9580752B2 (en) 2008-12-24 2017-02-28 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
WO2010120814A1 (en) 2009-04-14 2010-10-21 Prometheus Laboratories Inc. Inflammatory bowel disease prognostics
EP3309556B1 (en) 2009-06-25 2020-04-08 Prometheus Biosciences, Inc. Methods for diagnosing irritable bowel syndrome
WO2011060098A1 (en) 2009-11-10 2011-05-19 Prometheus Laboratories Inc. Methods for predicting post-surgery risk associated with ileal pouch-anal anastomosis
NZ609363A (en) 2010-10-18 2015-04-24 Nestec Sa Methods for determining anti-drug antibody isotypes
AU2012253422B2 (en) 2011-05-10 2015-08-13 Société des Produits Nestlé S.A. Methods of disease activity profiling for personalized therapy management
WO2012158831A1 (en) 2011-05-16 2012-11-22 Prometheus Laboratories Inc. Performance of a biomarker panel for irritable bowel syndrome
JP2015502740A (ja) 2011-10-21 2015-01-29 ネステク ソシエテ アノニム 炎症性腸疾患の診断を改善するための方法
CN102707055A (zh) * 2012-06-11 2012-10-03 郑州安图绿科生物工程有限公司 一种联合或单独检测自身免疫性肝病相关抗体的试剂盒及其检测方法
CN102955027A (zh) * 2012-06-11 2013-03-06 郑州安图绿科生物工程有限公司 检测自身免疫性肝病相关抗体抗lc-1抗体的试剂盒及其检测方法
EP2904405B1 (en) 2012-10-05 2017-05-31 Nestec S.A. Methods for predicting and monitoring mucosal healing
KR20230109779A (ko) 2013-03-27 2023-07-20 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한섬유증 및 염증의 완화 및 반전
EP3022295A4 (en) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
CA2932569A1 (en) 2013-12-03 2015-06-11 Societe Des Produits Nestle S.A. Signaling pathways in tissues from inflammatory bowel disease patients
WO2015083087A1 (en) 2013-12-03 2015-06-11 Nestec S.A. Methods for predicting post-operative recurrence of crohn's disease
WO2015166461A1 (en) 2014-05-01 2015-11-05 Nestec S.A. Methods of selecting treatment regimen using tnf alpha and anti-tnf alpha drug levels
CA2964857A1 (en) 2014-10-20 2016-04-28 Nestec S.A. Methods for prediction of anti-tnf alpha drug levels and autoantibody formation
HK1244881A1 (zh) 2014-12-02 2018-08-17 Société des Produits Nestlé S.A. 建立维多珠单坑给药方案以治疗患有易激惹肠病的患者的方法
KR20240095481A (ko) 2016-03-17 2024-06-25 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법
EP3273238A1 (en) * 2016-07-22 2018-01-24 Universitätsklinikum Hamburg-Eppendorf Immunodiagnostic detection of anti-neutrophil antibodies
KR20200069333A (ko) 2017-10-10 2020-06-16 프로메테우스 바이오사이언시즈, 인크. 베돌리주맙 치료를 모니터링하는 방법
CN110604743B (zh) * 2019-07-23 2021-08-17 四川大学 中性粒细胞在制备治疗和/或预防自身免疫性肝炎的药物中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292667A (en) * 1988-06-29 1994-03-08 The General Hospital Corporation Detection and treatment of ulcerative colitis
US5091303A (en) * 1989-10-27 1992-02-25 The General Hospital Corporation Diagnosis of wegener's granulomatosis
WO1992002819A2 (en) * 1990-08-10 1992-02-20 The Regents Of The University Of California Assay for ulcerative colitis and primary sclerosing cholangitis
US5238813A (en) * 1990-12-18 1993-08-24 Washington University Diagnostic method for nephritis
GB9126918D0 (en) * 1991-12-19 1992-02-19 Univ London Members of specific binding pairs;methods of their making and using
DK0615129T3 (da) * 1993-03-10 2000-08-07 Cedars Sinai Medical Center Fremgangsmåder til selektiv påvisning af perinukleært anti-neutrophilt cytoplasmatisk antistof fra ulcerativ colitis eller

Also Published As

Publication number Publication date
CA2223642A1 (en) 1996-12-19
US5830675A (en) 1998-11-03
AU6040496A (en) 1996-12-30
MX9709440A (es) 1998-06-30
CA2223642C (en) 2005-08-16
NO975688D0 (no) 1997-12-05
AU705480B2 (en) 1999-05-20
EP0846266B1 (en) 2003-01-29
JPH11507130A (ja) 1999-06-22
EP0846266A4 (en) 2001-08-29
NZ310079A (en) 2000-02-28
JP3386815B2 (ja) 2003-03-17
WO1996041183A1 (en) 1996-12-19
NO321090B1 (no) 2006-03-13
EP0846266A1 (en) 1998-06-10
ATE231972T1 (de) 2003-02-15
IL122480A0 (en) 1998-06-15
DE69626026T2 (de) 2004-01-22
DE69626026D1 (de) 2003-03-06

Similar Documents

Publication Publication Date Title
NO975688L (no) Differensialanalyse for ulcerös kolitt, primær skleroserende cholangitt og type 1 autoimmunhepatitt
EP0615129A3 (en) Method for selectively detecting cytoplasmic, anti-neutrophilic antibodies to ulcerative colitis or primary sclerosing cholangitis.
DK309285D0 (da) Fremgangsmaade til bestemmelse af immunkomplekser i serum
CY1107621T1 (el) Μεθοδος ανιχνευσης αντισωματων σε ενα δειγμα
ES2185623T3 (es) Pruebas aloantigenicas mediante ensayo de union.
NO964015L (no) Fremgangsmåte for påvisning av kalpain-aktivering og identifisering av kalpain-inhibitorer
ES483606A1 (es) Metodo y su correspondiente kit de prueba para la deteccion-y-o determinacion de una inmunoglobulina especifica antige- nica.
EP0254081A3 (en) Method of detecting specific protein
BR9100924A (pt) Linha de celulas de hibridoma,mutantes,anticorpos,processo para a preparacao de uma linha de celulas de hibridoma,processo para a preparacao de anticorpos,processo e agente para a prova imunologica de metolacloro,derivado de metolacloro e processo para sua preparacao
ES8705232A1 (es) Un metodo para preparar un anticuerpo monoclonal destinado autilizarse como auxiliar de diagnostico para detectar cancerde pulmon
DE60038557D1 (en) Assay
DK0519536T3 (da) Diagnostisk fremgangsmåde
HU912200D0 (en) Method for immunological indication
ZA953432B (en) Method to identify immunocompromised patients at high risk for cryptococcosis
NO931613L (no) Fremgangsmaate for bestemming av sensiteten og/eller det spesifikke ved et proberingssystem for sporing av antistoffer
TW246718B (en) Immunoassay for detecting HCV IgM antibody

Legal Events

Date Code Title Description
MK1K Patent expired